Neutrophil Integrins in Defense against Drug-Resistant C. albicans
中性粒细胞整合素防御耐药白色念珠菌
基本信息
- 批准号:10488635
- 负责人:
- 金额:$ 32.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-18 至 2022-11-18
- 项目状态:已结题
- 来源:
- 关键词:Antibiotic ResistanceAntibioticsAntimicrobial ResistanceBacterial Antibiotic ResistanceBiomedical ResearchBiotechnologyCandida albicansCenters of Research ExcellenceCessation of lifeChemotherapy-Oncologic ProcedureClinicalClinical MedicineCommunicable DiseasesCommunitiesCore FacilityDedicationsDisciplineDrug resistanceEnsureEnvironmentFacultyFinancial HardshipFosteringFundingGenerationsGoalsHealthcareHospital CostsHospitalsInfectionInfrastructureInstitutionIntegrinsInternationalInterventionInvestmentsLaboratoriesLaboratory ResearchLongevityMedicalMentorsOrgan TransplantationParticipantPharmaceutical PreparationsPharmacologic SubstancePhasePilot ProjectsPrimary Health CareProgram DevelopmentResearchResearch PersonnelResistanceResortResourcesRhode IslandServicesTherapeuticTraining SupportUnited StatesUniversitiesWorkantimicrobial drugcareercareer developmentclinical practicecostdesigndrug discoverydrug resistant pathogeninnovationmicroorganismmultidisciplinaryneutrophilnovel strategiesnovel therapeutic interventionnovel therapeuticsprogramsresistance mechanismsuccess
项目摘要
Resistance to antimicrobial therapies is a national and international crisis that threatens clinical practice from
fundamental primary care to the most advanced medical interventions such as cancer chemotherapy and
organ transplantation. Much of what we take for granted in clinical medicine could become too risky as
microorganisms have become increasingly resistant to our newest medications and our antibiotics of last
resort. Antimicrobial resistance also adds enormous costs to health care, exceeding $21 billion in the United
States alone. Compounding this problem is the fact that pharmaceutical companies have largely abandoned
antibiotic development programs. As an alternative to large pharmaceutical companies, academic institutions
and biotech startups can step in to refill the antibiotic pipeline using novel approaches to drug discovery. The
principal objective of this Phase I COBRE application is to build a unique, multi-disciplinary center of
excellence to study mechanisms of antimicrobial resistance and develop therapeutic countermeasures. The
long-term goal of the Center for Antimicrobial Resistance and Therapeutic Discovery (CARTD) at The Miriam
Hospital of the Lifespan Hospital Group is to develop new therapies for infections caused by drug resistant
pathogens. This long-term goal will be attained with shorter-term objectives of developing a new generation of
junior investigators who study mechanisms of resistance, characterize new targets, and study new and existing
compounds. CARTD will integrate their work with mentors and established investigators at the institution and
develop core facilities to enhance research capabilities in the field of antimicrobial resistance and the discovery
of new therapeutics. To achieve these objectives, the CARTD will complete the following specific aims: 1.
Consolidate existing researchers into a dynamic, interactive center of excellence across The Miriam Hospital,
and its academic partners in Rhode Island, including Brown University. 2. Foster the research programs and
career development of junior investigators in the field of antimicrobial resistance and studies of novel
therapeutic approaches. 3. Support new institutional research with pilot project funding. 4. Establish critical
infrastructure with new core laboratories to facilitate cutting edge research in antimicrobial resistance and
therapeutic discovery, and serve as a unique technical resources to other COBRE research programs, other
institutional researchers, and investigators in the region.
抗微生物药物耐药性是一项威胁临床实践的国家和国际危机
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian William LeBlanc其他文献
Brian William LeBlanc的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian William LeBlanc', 18)}}的其他基金
Neutrophil Integrins in Defense against Drug-Resistant C. albicans
中性粒细胞整合素防御耐药白色念珠菌
- 批准号:
10224231 - 财政年份:2020
- 资助金额:
$ 32.22万 - 项目类别:
Neutrophil Integrins in Defense against Drug-Resistant C. albicans
中性粒细胞整合素防御耐药白色念珠菌
- 批准号:
10216507 - 财政年份:2020
- 资助金额:
$ 32.22万 - 项目类别:
相似海外基金
Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
- 批准号:
2902098 - 财政年份:2024
- 资助金额:
$ 32.22万 - 项目类别:
Studentship
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
- 批准号:
BB/Y004035/1 - 财政年份:2024
- 资助金额:
$ 32.22万 - 项目类别:
Research Grant
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
- 批准号:
EP/Z533026/1 - 财政年份:2024
- 资助金额:
$ 32.22万 - 项目类别:
Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
- 批准号:
FT230100468 - 财政年份:2024
- 资助金额:
$ 32.22万 - 项目类别:
ARC Future Fellowships
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
- 批准号:
EP/Y023528/1 - 财政年份:2024
- 资助金额:
$ 32.22万 - 项目类别:
Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
- 批准号:
BB/Y007611/1 - 财政年份:2024
- 资助金额:
$ 32.22万 - 项目类别:
Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
- 批准号:
MR/Y033809/1 - 财政年份:2024
- 资助金额:
$ 32.22万 - 项目类别:
Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
- 批准号:
494853 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
- 批准号:
2884862 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
- 批准号:
2904356 - 财政年份:2023
- 资助金额:
$ 32.22万 - 项目类别:
Studentship